CNS Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
berubicin (RTA 744) / CNS Pharma, WPD Pharma
2019-004015-31: A phase 2 open-label study of Berubicin in adult patients with Recurrent Gliobastoma Multiforme after failure of standard first line therapy

Not yet recruiting
2
61
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion
WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o.
Glioblastoma Multiforme, Glioblastoma Multiforme, Diseases [C] - Cancer [C04]
 
 
2021-003659-40: A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Un estudio de Berubicina en Pacientes Adultos con Gliobastoma Recidivante Multiforme

Not yet recruiting
2
210
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion, Capsule, hard, Cecenu®
CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc.
Glioblastoma Multiforme (WHO Grade IV) Glioblastoma Multiforme (grado IV de la OMS), Glioblastoma multiforme (GBM) glioblastoma multiforme (GBM), Diseases [C] - Cancer [C04]
 
 
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
02/26
03/26
2021-006028-41: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN Ocena bezpieczeństwa i skuteczności berubicyny w leczeniu chłoniaków ośrodkowego układu nerwowego- BERUBICYNA

Ongoing
1/2
60
Europe
Berubicin, WP 744, Lyophilisate for solution for injection
Pomorski Uniwersytet Medyczny w Szczecinie, Medical Research Agency
Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI) Pierwotny chłoniak ośrodkowego układu nerwowego (PCNSL) i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego (NHL-CNSI), Primary central nervous system lymphoma and secondary non-Hodgkin's lymphoma with central nervous system involvement Pierwotny chłoniak ośrodkowego układu nerwowego i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego, Diseases [C] - Cancer [C04]
 
 
NCT04915404 / 2019-004015-31: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Terminated
1/2
5
Europe
Berubicin Hydrochloride
WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials, National Center for Research and Development, Poland
Recurrent Glioblastoma Multiforme
12/23
12/23
2019-004016-58: A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomas

Not yet recruiting
1
35
Europe
Berubicin, WP 744, Lyophilisate and solvent for solution for injection
WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o.
High Grade Gliomas, High Grade Gliomas, Diseases [C] - Cancer [C04]
 
 
NCT05082493 / 2019-004016-58: A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

Withdrawn
1
35
NA
Berubicin Hydrochloride
WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials
High Grade Glioma
12/23
12/23
WP1122 / Moleculin, CNS Pharma, WPD Pharma
WP1122, NCT05365321: Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19

Not yet recruiting
1/2
75
RoW
WP1122
Andrei Carvalho Sposito
COVID-19, Mechanical Ventilation Complication, COVID-19 Acute Respiratory Distress Syndrome
02/23
10/23
WP1874 / CNS Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
berubicin (RTA 744) / CNS Pharma, WPD Pharma
2019-004015-31: A phase 2 open-label study of Berubicin in adult patients with Recurrent Gliobastoma Multiforme after failure of standard first line therapy

Not yet recruiting
2
61
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion
WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o.
Glioblastoma Multiforme, Glioblastoma Multiforme, Diseases [C] - Cancer [C04]
 
 
2021-003659-40: A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Un estudio de Berubicina en Pacientes Adultos con Gliobastoma Recidivante Multiforme

Not yet recruiting
2
210
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion, Capsule, hard, Cecenu®
CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc.
Glioblastoma Multiforme (WHO Grade IV) Glioblastoma Multiforme (grado IV de la OMS), Glioblastoma multiforme (GBM) glioblastoma multiforme (GBM), Diseases [C] - Cancer [C04]
 
 
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
02/26
03/26
2021-006028-41: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN Ocena bezpieczeństwa i skuteczności berubicyny w leczeniu chłoniaków ośrodkowego układu nerwowego- BERUBICYNA

Ongoing
1/2
60
Europe
Berubicin, WP 744, Lyophilisate for solution for injection
Pomorski Uniwersytet Medyczny w Szczecinie, Medical Research Agency
Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI) Pierwotny chłoniak ośrodkowego układu nerwowego (PCNSL) i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego (NHL-CNSI), Primary central nervous system lymphoma and secondary non-Hodgkin's lymphoma with central nervous system involvement Pierwotny chłoniak ośrodkowego układu nerwowego i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego, Diseases [C] - Cancer [C04]
 
 
NCT04915404 / 2019-004015-31: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Terminated
1/2
5
Europe
Berubicin Hydrochloride
WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials, National Center for Research and Development, Poland
Recurrent Glioblastoma Multiforme
12/23
12/23
2019-004016-58: A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomas

Not yet recruiting
1
35
Europe
Berubicin, WP 744, Lyophilisate and solvent for solution for injection
WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o.
High Grade Gliomas, High Grade Gliomas, Diseases [C] - Cancer [C04]
 
 
NCT05082493 / 2019-004016-58: A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

Withdrawn
1
35
NA
Berubicin Hydrochloride
WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials
High Grade Glioma
12/23
12/23
WP1122 / Moleculin, CNS Pharma, WPD Pharma
WP1122, NCT05365321: Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19

Not yet recruiting
1/2
75
RoW
WP1122
Andrei Carvalho Sposito
COVID-19, Mechanical Ventilation Complication, COVID-19 Acute Respiratory Distress Syndrome
02/23
10/23
WP1874 / CNS Pharma
No trials found

Download Options